DelMar Pharmaceuticals, Inc. (DMPI) Given Consensus Recommendation of “Buy” by Analysts

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) has been assigned an average broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.

Brokers have set a 1-year consensus target price of $11.16 for the company and are predicting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also assigned DelMar Pharmaceuticals an industry rank of 106 out of 265 based on the ratings given to its competitors.

A number of equities research analysts recently weighed in on DMPI shares. HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 29th. Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th.

In other news, CEO Saiid Zarrabian acquired 60,900 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $0.82 per share, for a total transaction of $49,938.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders acquired a total of 108,400 shares of company stock worth $89,713 over the last quarter.

Several large investors have recently bought and sold shares of DMPI. Franklin Resources Inc. bought a new position in shares of DelMar Pharmaceuticals in the 2nd quarter worth $2,477,000. Sabby Management LLC bought a new position in shares of DelMar Pharmaceuticals in the 2nd quarter worth $1,484,000. Finally, Susquehanna International Group LLP bought a new position in shares of DelMar Pharmaceuticals in the 3rd quarter worth $306,000. Institutional investors and hedge funds own 16.91% of the company’s stock.

Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) traded down $0.05 on Wednesday, hitting $0.88. The stock had a trading volume of 316,400 shares, compared to its average volume of 436,793. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39.

DelMar Pharmaceuticals (NASDAQ:DMPI) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). research analysts predict that DelMar Pharmaceuticals will post -0.6 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/12/06/delmar-pharmaceuticals-inc-dmpi-given-consensus-recommendation-of-buy-by-analysts.html.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply